COMPLETED TRIALS

The clinical trials listed in this section have been completed.

1. Rectal Cancer | TROG/AGITG 01.04
2. Advanced Gastric Cancer | AG9801
3. Gastric Cancer (Operable) | AG9601
4. Hepatocellular Cancer | AG0001H
5. Metastatic Colorectal Cancer | AG9401
6. Gastric/Lower Oesophageal Cancer | MAGIC: ST02
7. Metastatic Pancreas Cancer | NCIC PA.3
8. Oesophagus Cancer | IG9401

1.Rectal Cancer | TROG/AGITG 01.04 - Click for Trial Schema

A randomised trial of preoperative radiotherapy for stage T3 Adenocarcinoma of rectum.

Principal Investigators
Associate Professor Sam Ngan Division of Radiation Oncology Peter MacCallum Cancer Centre VIC Australia.

2.Advanced Gastric Cancer | AG9801 - Click for Trial Schema

A phase II study of irinotecan, leucovorin and 5-fluorouracil in advanced gastric cancer.

This trial was designed to assess the efficacy and toxicity of irinotecan, leucovorin, and 5-flourouracil for patients with advanced gastric cancer.

Principal Investigators
Professor Stephen Ackland Medical Oncologist Newcastle Mater Misericordiae Hospital, NSW
Doctor David Storey Upper GI Surgeon Royal Prince Alfred Hospital, NSW

Supported by
Pharmacia P/L (Australia)

3.Gastric Cancer (Operable) | AG9601 - Click for Trial Schema

A phase II feasibility study of pre-operative and post-operative chemotherapy using epirubicin, cisplatin and protracted venous infusion fluorouracil (ECF) in patients with advanced but operable gastric cancer.

Surgery is the standard treatment for cancers of the stomach (gastric) and lower oesophagus (gullet) that can be removed with an operation, but the cancer often comes back (recurs) despite the best surgery. This trial will determine if adding chemotherapy two months before and two months after surgery improves recurrence and cure rates.

Principal Investigators
Professor Michael Findlay Medical Oncologist Auckland Hospital, NZ
Doctor David Storey Upper GI Surgeon Royal Prince Alfred Hospital, NSW

Supported by
Pharmacia Australia P/L
NHMRC Clinical Trials Centre (Australia)

4.Hepatocellular Cancer | AG0001H - Click for Trial Schema

Pilot phase II study of Sandostatin LAR® in patients with advanced hepatocellular carcinoma.

Advanced hepatocellular carcinoma is a disease with minimal effective treatment options available and a very poor prognosis. This study hopes to determine the feasibility of delivering a treatment that has produced encouraging results in another small randomised study. The study determines whether treating people with Sandostatin LAR® means that they live longer and feel better. The study will also tell us whether the treatment has any impact on tumour growth and to see if the effect of Sandostatin LAR® on tumour growth is different when the tumour has somatostatin receptors. These results will help to decide whether or not to continue investigating this treatment in larger randomised studies.

Principal Investigators
Associate Professor Jonathon Cebon Medical Oncologist Austin Health, VIC
Professor Michael Findlay Medical Oncologist Auckland Hospital, NZ

Supported by
Novartis Pharmaceuticals Australia P/L

5.Metastatic Colorectal Cancer | AG9401 - Click for Trial Schema

A randomised trial of early chemotherapy in asymptomatic metastatic colorectal cancer.

People with advanced colon cancer sometimes feel completely well when they are first diagnosed. This study asks the question, “Is it better to start chemotherapy immediately - causing serious side-effects - or delay until symptoms appear?” The results of this study demonstrated that delaying chemotherapy was as safe as giving treatment straightaway and allowed better quality of life in the meantime.

Principal Investigators
Professor Stephen Ackland Medical Oncologist Newcastle Mater Misericordiae Hospital, NSW

Supported by
The Cancer Council NSW

6.Gastric/Lower Oesophageal Cancer | MAGIC: ST02 - Click for Trial Schema

A Randomised, Controlled Trial of Pre- and Post-Operative Chemotherapy in Patients with Operable Gastric and Lower Oesophageal Cancer.

Surgery is the standard treatment for cancers of the stomach (gastric) and lower oesophagus (gullet) that can be removed with an operation, but the cancer often comes back (recurs) despite the best surgery. This trial will determine if adding chemotherapy two months before and two months after surgery improves recurrence and cure rates.

Principal Investigators
Professor Michael Findlay Medical Oncologist Auckland Hospital, NZ

7.Metastatic Pancreas Cancer | NCIC PA.3 - Click for Trial Schema

A randomised placebo controlled study of OSI-774 (Tarceva™) plus gemcitabine in patients with locally advanced, unresectable or metastatic pancreatic cancer.

When cancers of the pancreas are detected they have often spread to other parts of the body (metastases), or they return (recur) after surgery. The best treatment in this situation is chemotherapy with a drug called gemcitabine. As a result of chemotherapy, in many cases, the cancer will stop growing or get smaller for a time. In spite of chemotherapy, many of the cancers will start growing or return after a period of time. This trial will determine if a new drug, OSI-774 (Tarceva™) given with chemotherapy will result in people living longer and with better quality of life.

Principal Investigators
Associate Professor David Goldstein Medical Oncologist Prince of Wales Hospital, NSW

Supported by
OSI Pharmaceuticals Inc. (USA)

8.Oesophagus Cancer | IG9401 - Click for Trial Schema

A randomised phase III clinical trial comparing surgery alone with concurrent pre-operative chemotherapy and radiation followed by surgery alone for resectable carcinoma of the oesophagus.

Surgery is the standard treatment for cancers of the oesophagus (gullet). However, the cancer often comes back (recurs) despite the best surgery. This trial will determine if adding chemotherapy and radiation therapy before surgery improves recurrence and cure rates.

Principal Investigators
Associate Professor Bryan Burmeister Radiation Oncologist Princess Alexandra Hospital, QLD

Supported by
Funded for the first three years by NHMRC (Australia)